文献速递儿科与产科急症重症综合管理与镇静镇痛

急性COVID-19或MIS-C住院儿童的谵妄:2020-2021年全球COVID-19神经功能障碍联盟研究的二次分析

Delirium in Children Hospitalized with Acute COVID-19 or MIS-C: Secondary Analysis of the 2020-2021 Global Consortium Study of Neurologic Dysfunction in COVID-19.
PubMed 文献 · Neurocrit Care · 2026-04-06
一句话结论多中心队列中,SARS-CoV-2相关疾病住院儿童谵妄发生率为1.8%,谵妄与全身炎症、严重神经损伤及更差临床结局相关。

该研究为多中心前瞻性观察队列的二次分析,纳入2020年1月1日至2021年7月31日全球COVID-19神经功能障碍联盟研究中46家医院、10个国家的住院儿童(<18岁),确诊急性COVID-19或MIS-C。3211例患者中57例(1.8%)记录到谵妄,MIS-C中谵妄发生率高于急性COVID-19(3.6% vs 1.5%,p=0.004)。谵妄患儿炎症标志物更高、严重神经表现更频繁、接受更多神经诊断检查,接受脑电图检查者异常普遍(n=23)。谵妄与更长住院时间(中位17 vs 4天,p<0.001)、更高死亡率(7.5% vs 1.1%,p=0.01)及更差功能结局相关。结论强调对SARS-CoV-2相关疾病住院儿童进行常规谵妄筛查和干预的重要性。

要点

  • 3211例住院儿童中57例(1.8%)记录到谵妄,MIS-C中谵妄发生率高于急性COVID-19(3.6% vs 1.5%,p=0.004)。
  • 谵妄患儿炎症标志物(如C反应蛋白、铁蛋白、D-二聚体、降钙素原)更高,严重神经表现更频繁(均p<0.001)。
  • 谵妄患儿住院时间更长(中位17 vs 4天,p<0.001)、死亡率更高(7.5% vs 1.1%,p=0.01)。
  • 谵妄患儿出院时新发残疾率更高(PCPC 22.5% vs 1.7%,p<0.001;FSS 22.7% vs 2.1%,p=0.001)。
  • 作者认为对SARS-CoV-2相关疾病住院儿童应进行常规谵妄筛查和干预。

适用人群与场景

  • 纳入全球COVID-19神经功能障碍联盟研究中46家医院、10个国家的住院儿童(<18岁),确诊急性COVID-19感染或MIS-C,入组时间2020年1月1日至2021年7月31日。

研究设计与关键结果

  • 研究类型为多中心前瞻性观察队列研究的二次分析,纳入3211例患者,57例(1.8%)记录到谵妄。
  • MIS-C中谵妄发生率高于急性COVID-19(3.6% vs 1.5%,p=0.004)。
  • 谵妄患儿炎症标志物(如C反应蛋白、铁蛋白、D-二聚体、降钙素原)更高,严重神经表现更频繁(均p<0.001),接受更多神经诊断检查(p<0.001)。
  • 接受脑电图检查的谵妄患儿中异常普遍(n=23)。
  • 谵妄与更长住院时间(中位17 vs 4天,p<0.001)、更高死亡率(7.5% vs 1.1%,p=0.01)相关。
  • 谵妄患儿出院时新发残疾率更高(PCPC 22.5% vs 1.7%,p<0.001;FSS 22.7% vs 2.1%,p=0.001)。

证据类型、等级与局限

  • 证据类型:多中心前瞻性观察队列研究的二次分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,这些发现强调了对SARS-CoV-2相关疾病及其他炎症性疾病住院儿童进行常规谵妄筛查和干预的重要性。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND/OBJECTIVE: The aims of this study were to describe pediatric delirium and its association with inflammatory, neurodiagnostic, and clinical severity profiles in children hospitalized with acute coronavirus disease 2019 (COVID-19) infection or multisystem inflammatory syndrome in children (MIS-C).

METHODS: We performed a secondary analysis of a multicenter, prospective observational cohort study including hospitalized children (< 18 years) with confirmed acute COVID-19 infection or MIS-C enrolled between 1 January 2020 and 31 July 2021 at 46 hospitals across ten countries participating in the Global Consortium Study of Neurologic Dysfunction in COVID-19 (GCS-NeuroCOVID).

RESULTS: Among 3211 patients, 57 (1.8%) had documented delirium. Delirium was more common in MIS-C than in acute COVID-19 (3.6% vs. 1.5%, p = 0.004). Children with delirium had higher inflammatory markers (e.g., C-reactive protein, ferritin, D-dimer, procalcitonin) and more frequently presented with severe neurologic manifestations (all p < 0.001). Patients with delirium underwent more neurodiagnostic testing (p < 0.001). Among children with delirium who received electroencephalogram (EEG) testing, abnormalities were universal (n = 23). Delirium was associated with longer hospital stays (median 17 vs. 4 days; p < 0.001), higher mortality (7.5% vs. 1.1%; p = 0.01), and worse functional outcomes, including higher rates of new disability at discharge as assessed by Pediatric Cerebral Performance Category (PCPC; 22.5% vs. 1.7%, p < 0.001) and functional status scale (FSS; 22.7% vs. 2.1%, p = 0.001).

CONCLUSIONS: Delirium in a select group of patients with pediatric severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related illness was associated with systemic inflammation, severe neurologic injury, and worse clinical outcomes in a multicenter cohort. These findings underscore the importance of routine delirium screening and intervention in children hospitalized with SARS-CoV-2-related illnesses and other inflammatory conditions.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Marupudi NK, Escobar-Serna DP, Dervan L, et al. Delirium in Children Hospitalized with Acute COVID-19 or MIS-C: Secondary Analysis of the 2020-2021 Global Consortium Study of Neurologic Dysfunction in COVID-19. Neurocrit Care. 2026. PMID: 41942816. doi:10.1007/s12028-026-02503-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。